These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR. Yamamoto M; Kakihana K; Ohashi K; Yamaguchi T; Tadokoro K; Akiyama H; Sakamaki H Int J Hematol; 2009 May; 89(4):482-488. PubMed ID: 19343480 [TBL] [Abstract][Full Text] [Related]
26. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615 [TBL] [Abstract][Full Text] [Related]
27. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors. Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815 [TBL] [Abstract][Full Text] [Related]
28. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037 [TBL] [Abstract][Full Text] [Related]
29. New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Mascarenhas CC; Cunha AF; Miranda EC; Zulli R; Silveira RA; Costa FF; Pagnano KB; De Souza CA Leuk Lymphoma; 2009 Jul; 50(7):1148-54. PubMed ID: 19557636 [TBL] [Abstract][Full Text] [Related]
30. SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia. Wang D; Zheng Y; Li J; Wu H; Li X; Tang Y; Liu Y; Li J; Sun R; Zhou Y; Sun J; Yang Y Eur J Pharmacol; 2017 Sep; 811():117-124. PubMed ID: 28595903 [TBL] [Abstract][Full Text] [Related]
31. A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Woessner DW; Eiring AM; Bruno BJ; Zabriskie MS; Reynolds KR; Miller GD; O'Hare T; Deininger MW; Lim CS Leukemia; 2015 Aug; 29(8):1668-75. PubMed ID: 25721898 [TBL] [Abstract][Full Text] [Related]
32. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842 [TBL] [Abstract][Full Text] [Related]
33. The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal. Kayastha GK; Ranjitkar N; Gurung R; Kc RK; Karki S; Shrestha R; Rajbhandari P; Thapa RK; Poudyal B; Acharya P; Roberts DJ; Hayes B; Zimmerman M; Basnyat B Br J Haematol; 2017 Jun; 177(6):1000-1007. PubMed ID: 28467002 [TBL] [Abstract][Full Text] [Related]
34. Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction. Mu H; Zou J; Zhang H Hematol Transfus Cell Ther; 2024 Feb; ():. PubMed ID: 38383224 [TBL] [Abstract][Full Text] [Related]
35. Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy. Sandt C; Feraud O; Bonnet ML; Desterke C; Khedhir R; Flamant S; Bailey CG; Rasko JEJ; Dumas P; Bennaceur-Griscelli A; Turhan AG Biochem Biophys Res Commun; 2018 Sep; 503(3):1861-1867. PubMed ID: 30057314 [TBL] [Abstract][Full Text] [Related]
36. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review. Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712 [TBL] [Abstract][Full Text] [Related]
37. Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand. Limsuwanachot N; Kongruang A; Rerkamnuaychoke B; Singdong R; Niparuck P; Jootar S; Siriboonpiputtana T Asian Pac J Cancer Prev; 2020 Jul; 21(7):2003-2012. PubMed ID: 32711426 [TBL] [Abstract][Full Text] [Related]
38. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins. You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193 [TBL] [Abstract][Full Text] [Related]
39. Clinico-laboratory pertinences and management of relapsed and refractory. Musteata V J BUON; 2021; 26(3):1165-1168. PubMed ID: 34268985 [TBL] [Abstract][Full Text] [Related]
40. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL. Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]